Scarica l'app Stockscreener
1.03
1.90%
-0.02
Dopo l'orario di chiusura:
1.01
-0.02
-1.94%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.05
Aprire:
$1.05
Volume 24 ore:
1.05M
Relative Volume:
1.03
Capitalizzazione di mercato:
$133.05M
Reddito:
-
Utile/perdita netta:
$-26.91M
Rapporto P/E:
-4.6818
EPS:
-0.22
Flusso di cassa netto:
$-19.57M
1 W Prestazione:
-12.71%
1M Prestazione:
+25.30%
6M Prestazione:
+70.25%
1 anno Prestazione:
-29.93%
Intervallo 1D:
$1.00
$1.10
Intervallo di 1 settimana:
$0.9604
$1.20
Portata 52W:
$0.5526
$1.66
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Nome
Atossa Therapeutics Inc
Settore
Industria
Telefono
206.588.0256
Indirizzo
10202 5TH AVENUE NE, SEATTLE, WA
Confronta ATOS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
1.03 | 133.05M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2018-01-26 | Iniziato | Maxim Group | Buy |
Atossa Therapeutics Inc Borsa (ATOS) Ultime notizie
Detecting price anomalies in Atossa Therapeutics Inc. with AIJuly 2025 Final Week & Risk Adjusted Buy and Sell Alerts - newser.com
Will Atossa Therapeutics Inc. stock benefit from commodity prices2025 Volatility Report & Verified Entry Point Signals - newser.com
Atossa Genetics (NASDAQ:ATOS) Cut to Strong Sell at Zacks Research - Defense World
Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Peoria Journal Star
Can Atossa Therapeutics Inc. (YAG2) stock stage a strong rebound this quarterMarket Sentiment Summary & AI Based Trade Execution Alerts - newser.com
Can Atossa Therapeutics Inc. stock sustain market leadership2025 Market Sentiment & Verified Technical Trade Signals - newser.com
Applying big data sentiment scoring on Atossa Therapeutics Inc.2025 Big Picture & Free AI Powered Buy and Sell Recommendations - newser.com
Strategies to average down on Atossa Therapeutics Inc.2025 Investor Takeaways & Real-Time Chart Breakout Alerts - newser.com
Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer - citybiz
Atossa Therapeutics Appoints New Chief Financial Officer - The Globe and Mail
NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Peoria Journal Star
Atossa Therapeutics to Present at the Maxim Growth Summit 2025 - Stock Titan
What moving averages say about Atossa Therapeutics Inc.Quarterly Market Summary & Risk Managed Investment Strategies - newser.com
How Atossa Therapeutics Inc. stock trades before earningsDollar Strength & Risk Managed Investment Strategies - newser.com
Atossa appoints Mark Daniel as CFO to prepare for commercial operations - Investing.com Nigeria
How to manage a losing position in Atossa Therapeutics Inc.Quarterly Investment Review & Daily Stock Trend Reports - newser.com
Atossa Therapeutics, Inc. Appoints Mark Daniel as Chief Financial Officer - MarketScreener
Atossa appoints Mark Daniel as CFO to prepare for commercial operations By Investing.com - Investing.com South Africa
Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness - PR Newswire
Atossa Therapeuticsappoints Mark Daniel as CFOSEC filing - MarketScreener
What MACD and RSI say about Atossa Therapeutics Inc.CEO Change & Growth Oriented Trading Recommendations - newser.com
Intraday pattern recognizer results for Atossa Therapeutics Inc.Insider Buying & Real-Time Market Trend Scan - newser.com
Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals - StreetInsider
Will Atossa Therapeutics Inc. stock split again soonMarket Activity Report & Reliable Volume Spike Alerts - newser.com
Published on: 2025-10-13 08:27:23 - newser.com
Atossa Therapeutics (ATOS) Strengthens Patent Portfolio for Z-en - GuruFocus
Regression analysis insights on Atossa Therapeutics Inc. performancePortfolio Gains Summary & High Accuracy Trade Signal Alerts - newser.com
Can a trend reversal in Atossa Therapeutics Inc. lead to recoveryEarnings Growth Report & Stepwise Swing Trade Plans - newser.com
Is Atossa Therapeutics Inc. stock ready for a breakoutJuly 2025 Sector Moves & Breakout Confirmation Alerts - newser.com
How to forecast Atossa Therapeutics Inc. trends using time seriesGap Down & Weekly Market Pulse Updates - newser.com
Is Atossa Therapeutics Inc. stock entering bullish territoryMarket Growth Report & Fast Moving Stock Trade Plans - newser.com
Comparing Atossa Therapeutics Inc. in custom built stock radars2025 Earnings Surprises & Stepwise Entry and Exit Trade Signals - newser.com
Published on: 2025-10-10 02:05:17 - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for Atossa Genetics (NASDAQ:ATOS) - MarketBeat
Can Atossa Therapeutics Inc. (YAG2) stock deliver double digit returnsOptions Play & Weekly Breakout Watchlists - newser.com
Signal strength of Atossa Therapeutics Inc. stock in tech scannersTrade Entry Report & Weekly Momentum Picks - newser.com
Can Atossa Therapeutics Inc. (YAG2) stock reach $200 price targetQuarterly Trade Report & Low Volatility Stock Recommendations - newser.com
Atossa Therapeutics (ATOS) Announces Upcoming Virtual Meeting - GuruFocus
Atossa streamlines breast cancer trial to focus on 2026 NDA plans - Investing.com
Atossa Therapeutics streamlines Evangeline breast cancer clinical trial to prioritize for 2026 NDA-enabling activities - MarketScreener
Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities - PR Newswire
Atossa Therapeutics Inc. stock retracement – recovery analysisEarnings Growth Report & Free Fast Gain Swing Trade Alerts - newser.com
Can Atossa Therapeutics Inc. stock hit analyst price targetsWeekly Risk Report & Consistent Income Trade Recommendations - newser.com
Atossa Therapeutics Inc Azioni (ATOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Atossa Therapeutics Inc Azioni (ATOS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Remmel H. Lawrence | Director |
Mar 26 '25 |
Buy |
0.70 |
10,000 |
7,000 |
10,257 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):